Aarti Pharmalabs Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mhl1ew4chtwru54qdod23sjv.pdf

Key Takeaways


Xanthine: Margin Pressure and the Volume Offset

Management: “We are utilizing our capacity to almost 90%. So unless we increase the capacity, the absolute number of the contribution won’t grow. So we are planning to look at opportunities to further debottleneck. So that overall market we are only capturing 15% to 20%. So there is enough opportunity which is available for us to grow.”

Backward Integration and Capacity Expansion

Rashesh Gogri: "One of the projects estimated to be completed in Q2 of this year is to manufacture the main raw material for Xanthine products, which is being currently imported. This will make us completely independent of China in this chemistry."

CDMO/CMO: The Growth Engine

Rashesh Gogri: "In CDMO, CMO space, generally we like to operate in phase 2 and upwards... we are not working on mad chemistry, we are working on scale ups and commercialization, the products which have potential of commercialization."

API and Intermediates: Regulated-Market Play

Rashesh Gogri: "And typically we like to do more value-added products as far as possible and do lesser and lesser of the lower value product, low margin product. So that is how we try to manage overall product mix."

Margins and Financial Levers


Guidance & Commitments

CommitmentSpecificsTimeline
Backward integration projectManufacture main Xanthine raw material in-house, eliminating China dependenceQ2 of this fiscal year
Atali greenfield Phase 1Complete first phase, focused on intermediates and CMO/CDMOH2 FY25
API plant utilization ramp-upRamp-up of the newly commissioned API block to beginH2 of this fiscal year
Tarapur project ramp-upFull ramp-up of Tarapur facilityNext 1 to 1.5 years
Overall EBITDA marginSustainable range of 20% plus/minus 2 percentage pointsOngoing
Top-line and EBITDA growth12% to 17% growth across all three segmentsOngoing
CDMO/CMO contributionReach 10% or more of overall businessThis fiscal year
Asset turnsImprove from ~1.5x toward 2xNo fixed date
Xanthine capacity utilizationNewly added 1,000 tons to reach 90% utilizationH2 of this fiscal year

Key Metrics

MetricQ1 FY24
Consolidated revenue₹458 cr, declined 6% YoY
Consolidated EBITDA₹85 cr, increased 6% YoY
Consolidated profit after tax₹48 cr, higher by 10% QoQ
EBITDA margin guidance (medium-term)12% to 17%
Sustainable EBITDA margin range~20%, plus or minus 2%
Xanthine revenue share (standalone)~50%, down from 55% in FY23
API and intermediates revenue share~43%
CDMO and CMO revenue share6%, potential to reach 10% or more this year
Xanthine capacity5,000 tons per annum, expanded from 4,000 via debottlenecking
Xanthine capacity utilization~90%
Xanthine global market share15% to 20%
CDMO and CMO products commercialized16 products, with 12 under development
API products commercialized50 APIs, around 12 to 15 actively sold in the US
R&D expense run-rate₹35 to ₹40 cr per quarter
Atali Greenfield project capex₹350 cr (first phase), overall capex of ₹500 cr